4583 — Chiome Bioscience Income Statement
0.000.00%
Last trade - 00:00
- ¥7bn
- ¥6bn
- ¥682m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 448 | 481 | 713 | 631 | 682 |
Cost of Revenue | |||||
Gross Profit | 285 | 245 | 422 | 349 | 399 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,841 | 1,763 | 2,184 | 1,883 | 1,885 |
Operating Profit | -1,393 | -1,283 | -1,471 | -1,253 | -1,203 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,401 | -1,291 | -1,466 | -1,238 | -1,215 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,404 | -1,294 | -1,480 | -1,243 | -1,220 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,404 | -1,294 | -1,480 | -1,243 | -1,220 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,404 | -1,294 | -1,480 | -1,243 | -1,220 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -44.8 | -36.1 | -34.5 | -28.3 | -24.7 |
Dividends per Share |